Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Features

Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option?

Shelley Wood

April 30, 2019

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Features

Despite New Findings, Optimal DAPT Duration Still Up in the Air

Todd Neale

December 10, 2014

Advertisement

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Roughly 80% of ESC Guideline Writers Have Financial COIs

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Twitter Takes on the Times of India, but the Question Persists: Is Foregoing a Stent an Option?

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Despite New Findings, Optimal DAPT Duration Still Up in the Air

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content